The global cell therapy market size was estimated at around USD 4.77 billion in 2023 and it is projected to hit around USD 36.83 billion by 2033, growing at a CAGR of 22.68% from 2024 to 2033. The cell therapy market is driven by rising prevalence of chronic diseases, advancements in gene editing technologies, personalized medicine, allogeneic cell therapies for scalability, and integration of artificial intelligence (ai).
The field of cell therapy has witnessed remarkable growth and innovation in recent years, positioning itself at the forefront of medical advancements. This article provides a comprehensive overview of the current state of the cell therapy market, highlighting key trends, challenges, and opportunities that shape its dynamic landscape.
The cell therapy market is experiencing robust growth, propelled by several key factors. One significant driver is the increasing prevalence of chronic diseases, such as cancer and cardiovascular disorders, prompting a heightened demand for innovative treatment modalities. The shift towards personalized medicine, facilitated by advancements in genomics and molecular biology, has also fueled market expansion. Furthermore, the continuous evolution of gene editing technologies, such as CRISPR-Cas9, enhances the precision and efficacy of cell therapies, contributing to their growing acceptance. Collaborations between pharmaceutical companies, biotechnology firms, and academic institutions further stimulate research and development activities, fostering innovation in the field. The rising interest in allogeneic cell therapies, offering scalable and off-the-shelf solutions, adds another dimension to the market's growth. As regulatory frameworks become more defined and streamlined, providing a clearer pathway for product approvals, the cell therapy market is poised for sustained expansion in the coming years.
In 2023, the autologous therapy segment dominated the market, holding a significant share of 92%. The growth of this segment can be attributed to the widespread adoption of various CAR-T therapies, known for their favorable outcomes in treating diverse cancers and genetic disorders. Several of these therapies have received approval from the FDA, and their increasing adoption is currently in progress. Notably, in February 2022, the U.S. FDA approved ciltacabtagene autoleucel (Carvykti) for adult patients with multiple myeloma unresponsive to refractory therapeutics or experiencing relapse after treatment.
Looking ahead, the allogeneic cell therapy segment is expected to experience substantial growth in the market from 2024 to 2033. This growth is driven by the high adoption of allogeneic therapies in designing innovative therapeutic regimens. The global pipeline currently boasts 542 active allogenic CAR-T agents, with many showing promising outcomes. For instance, Adaptimmune Ltd. has collaborated with Genentech to explore the utility of allogeneic therapies derived from induced pluripotent stem cells (iPSCs) in creating T-cells with a higher proliferation capacity than mature T-cells
In 2023, the oncology segment emerged as the market leader, boasting the largest share of revenue. CAR T-cells specifically targeting CD19 have demonstrated notable success in achieving high rates of complete and enduring remissions among patients with acute lymphocytic leukemia (ALL). The continuous increase in FDA approvals for innovative therapies is poised to unlock further growth opportunities for the market. Notably, in October 2021, the U.S. FDA granted approval for brexucabtagene autoleucel (Tecartus), a CAR T therapy designed for individuals with B-cell precursor ALL who have not responded to prior treatment (refractory) or have experienced a relapse after treatment. This milestone marked brexucabtagene as the inaugural CAR T treatment approved for adults with ALL.
Looking ahead, the musculoskeletal disorders segment is anticipated to experience substantial market expansion in the coming years. Significant research efforts are underway to develop technologies capable of regenerating or restoring impaired musculoskeletal tissues. Researchers from diverse groups are exploring clinically applicable cell types for therapies addressing musculoskeletal tissue degeneration. Additionally, there is exploration into the direct application of engineered or native skeletal progenitor cells to stimulate tissue repair and rejuvenate musculoskeletal tissues, driving growth within the segment.
In 2023, North America claimed the largest revenue share, accounting for 59%. This dominance is attributed to collaborative research initiatives between research institutes and pharmaceutical giants, fostering emerging advancements through numerous partnerships. A noteworthy collaboration occurred in June 2022 when Immatics partnered with Bristol Myers Squibb to develop Gamma Delta Allogeneic Cell Therapy Programs. The availability of substantial funds from government organizations significantly contributes to market growth in the U.S. An example is Cellino Biotech, which, in January 2022, raised approximately USD 80 million through a Series A financing round from investors like 8VC and Felicis Ventures.
Asia Pacific is anticipated to register a substantial Compound Annual Growth Rate (CAGR) during the forecast period, driven by the increasing demand for cell therapy in the region. Factors such as growing awareness about novel therapies, increased investments, and anticipated favorable government policies are expected to accelerate market growth. For instance, in June 2022, Tessa Therapeutics Ltd. secured USD 126 million through series funding rounds to propel the development of next-generation cancer therapy. Likewise, the South Korean market is projected to exhibit lucrative growth due to strategic initiatives by local and international companies. A case in point is Panacell Biotech, which announced in August 2022 its plans to utilize Natural Killer (NK) cells, brown Adipose-Derived Stem Cells (ADSC), and exosomes for treating COVID-19 infection.
By Therapy Type
By Therapeutic Area
By Region
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Cell Therapy Market
5.1. COVID-19 Landscape: Cell Therapy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Cell Therapy Market, By Therapy Type
8.1. Cell Therapy Market, by Therapy Type, 2024-2033
8.1.1. Allogeneic Therapies
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Autologous Therapies
8.1.2.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global Cell Therapy Market, By Therapeutic Area
9.1. Cell Therapy Market, by Therapeutic Area, 2024-2033
9.1.1. Oncology
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Cardiovascular Disease (CVD)
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Musculoskeletal Disorders
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Dermatology
9.1.4.1. Market Revenue and Forecast (2021-2033)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global Cell Therapy Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
10.1.2. Market Revenue and Forecast, by Therapeutic Area (2021-2033)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
10.1.3.2. Market Revenue and Forecast, by Therapeutic Area (2021-2033)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
10.1.4.2. Market Revenue and Forecast, by Therapeutic Area (2021-2033)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
10.2.2. Market Revenue and Forecast, by Therapeutic Area (2021-2033)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
10.2.3.2. Market Revenue and Forecast, by Therapeutic Area (2021-2033)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
10.2.4.2. Market Revenue and Forecast, by Therapeutic Area (2021-2033)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
10.2.5.2. Market Revenue and Forecast, by Therapeutic Area (2021-2033)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
10.2.6.2. Market Revenue and Forecast, by Therapeutic Area (2021-2033)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
10.3.2. Market Revenue and Forecast, by Therapeutic Area (2021-2033)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
10.3.3.2. Market Revenue and Forecast, by Therapeutic Area (2021-2033)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
10.3.4.2. Market Revenue and Forecast, by Therapeutic Area (2021-2033)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
10.3.5.2. Market Revenue and Forecast, by Therapeutic Area (2021-2033)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
10.3.6.2. Market Revenue and Forecast, by Therapeutic Area (2021-2033)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
10.4.2. Market Revenue and Forecast, by Therapeutic Area (2021-2033)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
10.4.3.2. Market Revenue and Forecast, by Therapeutic Area (2021-2033)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
10.4.4.2. Market Revenue and Forecast, by Therapeutic Area (2021-2033)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
10.4.5.2. Market Revenue and Forecast, by Therapeutic Area (2021-2033)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
10.4.6.2. Market Revenue and Forecast, by Therapeutic Area (2021-2033)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
10.5.2. Market Revenue and Forecast, by Therapeutic Area (2021-2033)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
10.5.3.2. Market Revenue and Forecast, by Therapeutic Area (2021-2033)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
10.5.4.2. Market Revenue and Forecast, by Therapeutic Area (2021-2033)
Chapter 11. Company Profiles
11.1. Novartis AG
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Gilead Sciences, Inc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Bristol-Myers Squibb Company
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Johnson & Johnson Services, Inc
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. LTE Scientific
11.5. JCR Pharmaceuticals Co., Ltd.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. JW Therapeutics
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Atara Biotherapeutics
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Anterogen Co., Ltd.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. MEDIPOST
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. S. BIOMEDICS
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers